Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:CEP170-AKT3

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: CEP170-AKT3
	FusionPDB ID: 15794
	FusionGDB2.0 ID: 15794
		Hgene	Tgene
	Gene symbol	CEP170	AKT3
	Gene ID	9859	10000
	Gene name	centrosomal protein 170	AKT serine/threonine kinase 3
	Synonyms	FAM68A\|KAB\|KIAA0470	MPPH\|MPPH2\|PKB-GAMMA\|PKBG\|PRKBG\|RAC-PK-gamma\|RAC-gamma\|STK-2
	Cytomap	1q43	1q43-q44
	Type of gene	protein-coding	protein-coding
	Description	centrosomal protein of 170 kDaKARP-1-binding proteinXRCC5 binding proteincentrosomal protein 170kDa	RAC-gamma serine/threonine-protein kinasePKB gammaRAC-gamma serine/threonine protein kinasev-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma)
	Modification date	20200313	20200313
	UniProtAcc	Q9Y4F5 Main function of 5'-partner protein: FUNCTION: Plays a role in microtubule organization. {ECO:0000250\|UniProtKB:Q5SW79}.	Q9Y243 Main function of 5'-partner protein: FUNCTION: AKT3 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificity has been reported. AKT3 is the least studied AKT isoform. It plays an important role in brain development and is crucial for the viability of malignant glioma cells. AKT3 isoform may also be the key molecule in up-regulation and down-regulation of MMP13 via IL13. Required for the coordination of mitochondrial biogenesis with growth factor-induced increases in cellular energy demands. Down-regulation by RNA interference reduces the expression of the phosphorylated form of BAD, resulting in the induction of caspase-dependent apoptosis. {ECO:0000269\|PubMed:18524868, ECO:0000269\|PubMed:21191416}.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000366542, ENST00000366543, ENST00000366544, ENST00000468254, ENST00000481987, ENST00000490813,	ENST00000492957, ENST00000263826, ENST00000336199, ENST00000366539, ENST00000366540,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	12 X 9 X 10=1080	19 X 18 X 8=2736
	# samples	13	19
	** MAII score	log2(13/1080*10)=-3.05444778402238 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(19/2736*10)=-3.84799690655495 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: CEP170 [Title/Abstract] AND AKT3 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: CEP170 [Title/Abstract] AND AKT3 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	CEP170(243349081)-AKT3(243736350), # samples:3 AKT3(244006427)-CEP170(243336148), # samples:1
Anticipated loss of major functional domain due to fusion event.	CEP170-AKT3 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. CEP170-AKT3 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. CEP170-AKT3 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. CEP170-AKT3 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. AKT3-CEP170 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. AKT3-CEP170 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. AKT3-CEP170 seems lost the major protein functional domain in Hgene partner, which is a CGC due to the frame-shifted ORF. AKT3-CEP170 seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. AKT3-CEP170 seems lost the major protein functional domain in Hgene partner, which is a kinase due to the frame-shifted ORF. AKT3-CEP170 seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Tgene	AKT3	GO:0043536	positive regulation of blood vessel endothelial cell migration	28254819
Tgene	AKT3	GO:1905564	positive regulation of vascular endothelial cell proliferation	28254819

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr1:243349081/chr1:243736350)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across CEP170 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across AKT3 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000366542	CEP170	chr1	243349081	-	ENST00000336199	AKT3	chr1	243736350	-	2544	1618	52	2319	755
ENST00000366542	CEP170	chr1	243349081	-	ENST00000366540	AKT3	chr1	243736350	-	2344	1618	52	2319	755
ENST00000366542	CEP170	chr1	243349081	-	ENST00000366539	AKT3	chr1	243736350	-	5848	1618	52	2361	769
ENST00000366542	CEP170	chr1	243349081	-	ENST00000263826	AKT3	chr1	243736350	-	4429	1618	52	2361	769
ENST00000366542	CEP170	chr1	243349561	-	ENST00000336199	AKT3	chr1	243736350	-	2250	1324	52	2025	657
ENST00000366542	CEP170	chr1	243349561	-	ENST00000366540	AKT3	chr1	243736350	-	2050	1324	52	2025	657
ENST00000366542	CEP170	chr1	243349561	-	ENST00000366539	AKT3	chr1	243736350	-	5554	1324	52	2067	671
ENST00000366542	CEP170	chr1	243349561	-	ENST00000263826	AKT3	chr1	243736350	-	4135	1324	52	2067	671
ENST00000366543	CEP170	chr1	243349561	-	ENST00000336199	AKT3	chr1	243736350	-	2521	1595	323	2296	657
ENST00000366543	CEP170	chr1	243349561	-	ENST00000366540	AKT3	chr1	243736350	-	2321	1595	323	2296	657
ENST00000366543	CEP170	chr1	243349561	-	ENST00000366539	AKT3	chr1	243736350	-	5825	1595	323	2338	671
ENST00000366543	CEP170	chr1	243349561	-	ENST00000263826	AKT3	chr1	243736350	-	4406	1595	323	2338	671
ENST00000366544	CEP170	chr1	243349561	-	ENST00000336199	AKT3	chr1	243736350	-	2521	1595	323	2296	657
ENST00000366544	CEP170	chr1	243349561	-	ENST00000366540	AKT3	chr1	243736350	-	2321	1595	323	2296	657
ENST00000366544	CEP170	chr1	243349561	-	ENST00000366539	AKT3	chr1	243736350	-	5825	1595	323	2338	671
ENST00000366544	CEP170	chr1	243349561	-	ENST00000263826	AKT3	chr1	243736350	-	4406	1595	323	2338	671

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000366542	ENST00000336199	CEP170	chr1	243349081	-	AKT3	chr1	243736350	-	0.001934246	0.99806577
ENST00000366542	ENST00000366540	CEP170	chr1	243349081	-	AKT3	chr1	243736350	-	0.001972313	0.9980276
ENST00000366542	ENST00000366539	CEP170	chr1	243349081	-	AKT3	chr1	243736350	-	0.000872663	0.9991273
ENST00000366542	ENST00000263826	CEP170	chr1	243349081	-	AKT3	chr1	243736350	-	0.001261099	0.99873894
ENST00000366542	ENST00000336199	CEP170	chr1	243349561	-	AKT3	chr1	243736350	-	0.003175723	0.99682426
ENST00000366542	ENST00000366540	CEP170	chr1	243349561	-	AKT3	chr1	243736350	-	0.003301474	0.99669844
ENST00000366542	ENST00000366539	CEP170	chr1	243349561	-	AKT3	chr1	243736350	-	0.001301687	0.99869823
ENST00000366542	ENST00000263826	CEP170	chr1	243349561	-	AKT3	chr1	243736350	-	0.001952877	0.9980471
ENST00000366543	ENST00000336199	CEP170	chr1	243349561	-	AKT3	chr1	243736350	-	0.003209028	0.99679095
ENST00000366543	ENST00000366540	CEP170	chr1	243349561	-	AKT3	chr1	243736350	-	0.003247565	0.9967525
ENST00000366543	ENST00000366539	CEP170	chr1	243349561	-	AKT3	chr1	243736350	-	0.001282341	0.99871767
ENST00000366543	ENST00000263826	CEP170	chr1	243349561	-	AKT3	chr1	243736350	-	0.001965827	0.9980342
ENST00000366544	ENST00000336199	CEP170	chr1	243349561	-	AKT3	chr1	243736350	-	0.003209028	0.99679095
ENST00000366544	ENST00000366540	CEP170	chr1	243349561	-	AKT3	chr1	243736350	-	0.003247565	0.9967525
ENST00000366544	ENST00000366539	CEP170	chr1	243349561	-	AKT3	chr1	243736350	-	0.001282341	0.99871767
ENST00000366544	ENST00000263826	CEP170	chr1	243349561	-	AKT3	chr1	243736350	-	0.001965827	0.9980342

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for CEP170-AKT3

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
CEP170	chr1	243349081	AKT3	chr1	243736350	1618	522	NSEEVEARKMIDKLFFHLSRERVFSE
CEP170	chr1	243349561	AKT3	chr1	243736350	1324	424	KVQATEKHQDQAVLFFHLSRERVFSE
CEP170	chr1	243349561	AKT3	chr1	243736350	1595	424	KVQATEKHQDQAVLFFHLSRERVFSE

Top

Potential FusionNeoAntigen Information of CEP170-AKT3 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

CEP170-AKT3_243349081_243736350.msa
CEP170-AKT3_243349561_243736350.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-B27:04	ARKMIDKLF	0.9981	0.8807	6	15
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-B27:02	ARKMIDKLF	0.9973	0.8257	6	15
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-B27:05	ARKMIDKLF	0.997	0.9536	6	15
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-A74:03	KMIDKLFFH	0.9925	0.5461	8	17
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-A74:09	KMIDKLFFH	0.9925	0.5461	8	17
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-A74:11	KMIDKLFFH	0.9925	0.5461	8	17
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-A02:21	MIDKLFFHL	0.992	0.6173	9	18
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-A02:11	MIDKLFFHL	0.9897	0.5282	9	18
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-A02:04	MIDKLFFHL	0.9859	0.5802	9	18
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-A02:35	MIDKLFFHL	0.9795	0.524	9	18
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-A30:08	KMIDKLFFH	0.9668	0.7303	8	17
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-B15:03	RKMIDKLFF	0.2047	0.8592	7	16
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-B27:02	ARKMIDKLFF	1	0.7957	6	16
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-B27:05	ARKMIDKLFF	0.9999	0.943	6	16
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-B27:04	ARKMIDKLFF	0.9999	0.8721	6	16
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-B27:07	ARKMIDKLFF	0.9996	0.5286	6	16
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-A02:04	KMIDKLFFHL	0.9988	0.5358	8	18
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-A02:13	KMIDKLFFHL	0.9988	0.6272	8	18
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-A02:21	KMIDKLFFHL	0.9983	0.5507	8	18
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-A74:11	KLFFHLSRER	0.9919	0.5554	12	22
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-A74:09	KLFFHLSRER	0.9919	0.5554	12	22
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-A74:03	KLFFHLSRER	0.9919	0.5554	12	22
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-A31:02	KLFFHLSRER	0.9734	0.5346	12	22
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-C05:09	MIDKLFFHL	0.9999	0.9602	9	18
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-C04:07	MIDKLFFHL	0.9998	0.6946	9	18
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-C04:10	MIDKLFFHL	0.9998	0.665	9	18
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-C08:15	MIDKLFFHL	0.9997	0.9687	9	18
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-C04:06	MIDKLFFHL	0.9952	0.8027	9	18
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-A02:07	MIDKLFFHL	0.9906	0.5195	9	18
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-C07:95	ARKMIDKLF	0.9825	0.8379	6	15
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-C04:14	MIDKLFFHL	0.9722	0.7263	9	18
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-C08:04	MIDKLFFHL	0.9615	0.9746	9	18
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-C08:13	MIDKLFFHL	0.9615	0.9746	9	18
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-C07:05	ARKMIDKLF	0.9456	0.9698	6	15
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-B27:03	ARKMIDKLF	0.9386	0.9565	6	15
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-C07:27	ARKMIDKLF	0.9305	0.9696	6	15
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-C08:03	MIDKLFFHL	0.9096	0.9886	9	18
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-C07:19	ARKMIDKLF	0.8137	0.8864	6	15
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-C07:46	ARKMIDKLF	0.7054	0.9402	6	15
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-C12:16	ARKMIDKLF	0.0315	0.9691	6	15
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-B27:03	ARKMIDKLFF	0.9983	0.9459	6	16
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-A31:01	KLFFHLSRER	0.9926	0.5023	12	22
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-C04:03	MIDKLFFHL	0.9999	0.7435	9	18
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-C05:01	MIDKLFFHL	0.9999	0.9602	9	18
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-C04:01	MIDKLFFHL	0.9998	0.6946	9	18
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-C18:01	MIDKLFFHL	0.9998	0.7031	9	18
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-C08:02	MIDKLFFHL	0.9997	0.9687	9	18
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-B27:10	ARKMIDKLF	0.9978	0.9503	6	15
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-B27:08	ARKMIDKLF	0.9969	0.9122	6	15
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-B27:06	ARKMIDKLF	0.9959	0.8661	6	15
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-A74:01	KMIDKLFFH	0.9925	0.5461	8	17
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-A02:14	MIDKLFFHL	0.9923	0.5574	9	18
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-A02:06	MIDKLFFHL	0.992	0.6173	9	18
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-C04:04	MIDKLFFHL	0.9916	0.7716	9	18
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-C07:01	ARKMIDKLF	0.9861	0.8144	6	15
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-B27:09	ARKMIDKLF	0.9626	0.9476	6	15
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-C08:01	MIDKLFFHL	0.9096	0.9886	9	18
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-A69:01	MIDKLFFHL	0.8779	0.7311	9	18
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-C17:01	MIDKLFFHL	0.7735	0.8547	9	18
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-C07:22	ARKMIDKLF	0.7044	0.8331	6	15
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-C06:08	ARKMIDKLF	0.4757	0.9957	6	15
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-B48:02	RKMIDKLFF	0.2308	0.9388	7	16
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-B15:68	RKMIDKLFF	0.0845	0.7227	7	16
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-B15:54	RKMIDKLFF	0.0826	0.9382	7	16
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-B15:68	ARKMIDKLF	0.0385	0.8649	6	15
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-C06:02	ARKMIDKLF	0.0305	0.9967	6	15
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-C06:17	ARKMIDKLF	0.0305	0.9967	6	15
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-B27:08	ARKMIDKLFF	0.9999	0.8958	6	16
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-B27:10	ARKMIDKLFF	0.9999	0.947	6	16
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-B27:06	ARKMIDKLFF	0.9996	0.8676	6	16
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-B27:09	ARKMIDKLFF	0.9991	0.9412	6	16
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-A02:03	KMIDKLFFHL	0.999	0.5567	8	18
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-A02:06	KMIDKLFFHL	0.9983	0.5507	8	18
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-A32:01	KMIDKLFFHL	0.9975	0.9672	8	18
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	HLA-A74:01	KLFFHLSRER	0.9919	0.5554	12	22
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B38:01	KHQDQAVL	0.9988	0.956	6	14
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B38:02	KHQDQAVL	0.9987	0.9586	6	14
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:10	KHQDQAVL	0.9912	0.7819	6	14
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B38:01	HQDQAVLF	0.9236	0.9862	7	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B13:01	HQDQAVLF	0.9213	0.9921	7	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B38:02	HQDQAVLF	0.9178	0.9876	7	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:37	KHQDQAVL	0.6448	0.8244	6	14
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B14:01	DQAVLFFHL	0.9952	0.7912	9	18
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B14:02	DQAVLFFHL	0.9952	0.7912	9	18
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B39:01	EKHQDQAVL	0.9937	0.7526	5	14
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B14:01	EKHQDQAVL	0.99	0.8444	5	14
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B14:02	EKHQDQAVL	0.99	0.8444	5	14
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B39:24	EKHQDQAVL	0.9888	0.6231	5	14
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B38:02	EKHQDQAVL	0.9886	0.9299	5	14
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B39:01	KHQDQAVLF	0.9836	0.8043	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-A74:09	AVLFFHLSR	0.9817	0.6998	11	20
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-A74:11	AVLFFHLSR	0.9817	0.6998	11	20
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-A74:03	AVLFFHLSR	0.9817	0.6998	11	20
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B39:13	KHQDQAVLF	0.9683	0.8583	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B39:24	KHQDQAVLF	0.9654	0.6744	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B38:01	KHQDQAVLF	0.9652	0.9458	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B38:02	KHQDQAVLF	0.9652	0.9454	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-A31:02	AVLFFHLSR	0.9206	0.5656	11	20
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B48:01	HQDQAVLFF	0.8916	0.7999	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:10	EKHQDQAVL	0.8316	0.6723	5	14
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:25	HQDQAVLFF	0.8103	0.9751	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:01	HQDQAVLFF	0.8099	0.9569	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:10	KHQDQAVLF	0.7899	0.7062	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:02	HQDQAVLFF	0.7769	0.98	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:18	KHQDQAVLF	0.7494	0.8376	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:18	HQDQAVLFF	0.7427	0.876	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B39:01	HQDQAVLFF	0.7421	0.935	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B47:01	HQDQAVLFF	0.736	0.6294	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B39:13	HQDQAVLFF	0.7074	0.9638	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:37	EKHQDQAVL	0.6862	0.7285	5	14
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:03	HQDQAVLFF	0.6833	0.9318	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B38:01	HQDQAVLFF	0.656	0.9847	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:03	KHQDQAVLF	0.6475	0.8935	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B38:02	HQDQAVLFF	0.6407	0.9858	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:10	HQDQAVLFF	0.5978	0.762	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B13:01	HQDQAVLFF	0.5762	0.9877	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-A32:13	HQDQAVLFF	0.5213	0.91	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-A24:14	HQDQAVLFF	0.5035	0.5245	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:37	KHQDQAVLF	0.1285	0.7533	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B52:01	HQDQAVLFF	0.0681	0.9905	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B07:10	KHQDQAVLF	0.0191	0.5134	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B40:01	TEKHQDQAVL	0.987	0.5692	4	14
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B38:01	EKHQDQAVLF	0.9867	0.8767	5	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B38:01	KHQDQAVLFF	0.9857	0.9544	6	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B38:02	EKHQDQAVLF	0.9857	0.8796	5	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B38:02	KHQDQAVLFF	0.9825	0.9524	6	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-A74:11	VLFFHLSRER	0.9729	0.5686	12	22
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-A74:03	VLFFHLSRER	0.9729	0.5686	12	22
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-A74:09	VLFFHLSRER	0.9729	0.5686	12	22
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:18	EKHQDQAVLF	0.9332	0.669	5	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B13:01	KHQDQAVLFF	0.7632	0.9725	6	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B44:03	TEKHQDQAVLF	0.9984	0.8292	4	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B38:01	TEKHQDQAVLF	0.9809	0.9272	4	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B38:02	TEKHQDQAVLF	0.9763	0.9249	4	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-A31:02	AVLFFHLSRER	0.9563	0.5453	11	22
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C05:09	HQDQAVLF	1	0.9879	7	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C04:07	HQDQAVLF	1	0.9818	7	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C08:15	HQDQAVLF	0.9999	0.9939	7	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C04:10	HQDQAVLF	0.9999	0.981	7	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B39:05	KHQDQAVL	0.9986	0.8179	6	14
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B39:08	HQDQAVLF	0.8163	0.967	7	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C04:10	HQDQAVLFF	0.9988	0.9735	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C04:07	HQDQAVLFF	0.9986	0.9742	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C05:09	HQDQAVLFF	0.9985	0.9857	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C08:15	HQDQAVLFF	0.9957	0.9916	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B39:09	EKHQDQAVL	0.9949	0.668	5	14
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B39:12	EKHQDQAVL	0.9924	0.7572	5	14
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B39:05	EKHQDQAVL	0.989	0.7248	5	14
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B39:09	KHQDQAVLF	0.9853	0.6781	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-A31:01	AVLFFHLSR	0.9836	0.5586	11	20
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B39:12	KHQDQAVLF	0.9832	0.8091	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B39:05	KHQDQAVLF	0.9717	0.7896	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C07:27	KHQDQAVLF	0.9502	0.9493	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C07:95	KHQDQAVLF	0.9499	0.7479	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C07:19	KHQDQAVLF	0.9405	0.7592	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C07:05	KHQDQAVLF	0.9318	0.942	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B39:09	DQAVLFFHL	0.9316	0.8621	9	18
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C07:80	KHQDQAVLF	0.9293	0.9348	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C07:67	KHQDQAVLF	0.9293	0.9348	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C07:10	KHQDQAVLF	0.9269	0.9478	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C07:13	HQDQAVLFF	0.9186	0.9232	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C07:46	KHQDQAVLF	0.9141	0.8851	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C07:29	KHQDQAVLF	0.9139	0.8945	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C07:10	HQDQAVLFF	0.8913	0.9716	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C07:13	KHQDQAVLF	0.8912	0.8538	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C07:67	HQDQAVLFF	0.8821	0.9665	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C07:80	HQDQAVLFF	0.8821	0.9665	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:05	HQDQAVLFF	0.8785	0.9266	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C07:95	HQDQAVLFF	0.8718	0.8155	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C07:19	HQDQAVLFF	0.8549	0.8583	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C07:27	HQDQAVLFF	0.8542	0.9682	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:31	HQDQAVLFF	0.8479	0.9317	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-A01:02	HQDQAVLFF	0.8284	0.5514	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C08:03	HQDQAVLFF	0.8061	0.9913	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C03:14	HQDQAVLFF	0.798	0.9779	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C07:46	HQDQAVLFF	0.7779	0.944	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:21	HQDQAVLFF	0.7761	0.9548	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B39:09	HQDQAVLFF	0.7434	0.8567	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C04:06	HQDQAVLFF	0.7374	0.9723	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C08:13	HQDQAVLFF	0.6992	0.9766	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C08:04	HQDQAVLFF	0.6992	0.9766	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B51:07	DQAVLFFHL	0.6751	0.7965	9	18
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C04:14	HQDQAVLFF	0.6588	0.979	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B39:05	HQDQAVLFF	0.6424	0.9251	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B39:08	KHQDQAVLF	0.6274	0.8246	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B14:03	EKHQDQAVL	0.6016	0.8511	5	14
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B48:03	HQDQAVLFF	0.5996	0.5995	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B39:08	HQDQAVLFF	0.5661	0.969	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C04:14	KHQDQAVLF	0.427	0.9527	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-A02:07	HQDQAVLFF	0.3882	0.6216	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B44:08	HQDQAVLFF	0.3523	0.5852	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C02:06	HQDQAVLFF	0.2458	0.911	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B44:10	HQDQAVLFF	0.1194	0.6186	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C12:16	KHQDQAVLF	0.0446	0.9498	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B44:09	TEKHQDQAVLF	0.9988	0.5049	4	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B44:10	TEKHQDQAVLF	0.9946	0.5678	4	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-A31:01	AVLFFHLSRER	0.9748	0.5393	11	22
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C04:03	HQDQAVLF	1	0.9828	7	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C05:01	HQDQAVLF	1	0.9879	7	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C04:01	HQDQAVLF	1	0.9818	7	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C08:02	HQDQAVLF	0.9999	0.9939	7	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C18:01	HQDQAVLF	0.9999	0.9836	7	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B38:05	KHQDQAVL	0.9988	0.956	6	14
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:09	KHQDQAVL	0.9714	0.9271	6	14
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B39:11	KHQDQAVL	0.9472	0.7545	6	14
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B38:05	HQDQAVLF	0.9236	0.9862	7	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B39:11	HQDQAVLF	0.8392	0.9292	7	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B18:04	HQDQAVLF	0.817	0.946	7	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C04:03	HQDQAVLFF	0.9986	0.9781	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C04:01	HQDQAVLFF	0.9986	0.9742	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C05:01	HQDQAVLFF	0.9985	0.9857	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C18:01	HQDQAVLFF	0.9975	0.9774	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C08:02	HQDQAVLFF	0.9957	0.9916	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B39:31	EKHQDQAVL	0.9942	0.7536	5	14
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B39:31	KHQDQAVLF	0.9854	0.8059	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B39:02	KHQDQAVLF	0.9848	0.8483	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-A74:01	AVLFFHLSR	0.9817	0.6998	11	20
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B38:05	KHQDQAVLF	0.9652	0.9458	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C07:01	KHQDQAVLF	0.9523	0.7331	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C07:17	KHQDQAVLF	0.9332	0.9446	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B39:31	DQAVLFFHL	0.9331	0.958	9	18
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C07:02	KHQDQAVLF	0.9293	0.9348	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C07:02	HQDQAVLFF	0.8821	0.9665	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:20	HQDQAVLFF	0.8779	0.9569	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C07:17	HQDQAVLFF	0.8715	0.9713	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:50	HQDQAVLFF	0.8626	0.9445	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C07:01	HQDQAVLFF	0.858	0.8174	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B35:28	HQDQAVLFF	0.8279	0.9586	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:39	HQDQAVLFF	0.8216	0.9512	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B35:20	HQDQAVLFF	0.821	0.9599	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:33	HQDQAVLFF	0.8099	0.9569	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:34	HQDQAVLFF	0.8099	0.9569	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:125	HQDQAVLFF	0.8099	0.9569	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C07:04	HQDQAVLFF	0.8099	0.968	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:09	EKHQDQAVL	0.8071	0.7825	5	14
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C08:01	HQDQAVLFF	0.8061	0.9913	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B48:02	HQDQAVLFF	0.8023	0.946	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B39:31	HQDQAVLFF	0.8016	0.9363	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:12	HQDQAVLFF	0.7968	0.8864	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:27	HQDQAVLFF	0.7941	0.9633	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:135	HQDQAVLFF	0.7796	0.965	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B48:02	KHQDQAVLF	0.7739	0.9125	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B39:02	HQDQAVLFF	0.7729	0.96	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C18:01	KHQDQAVLF	0.7729	0.9503	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C07:22	KHQDQAVLF	0.7678	0.6902	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B39:11	EKHQDQAVL	0.7247	0.7394	5	14
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C04:04	HQDQAVLFF	0.7229	0.9686	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C03:67	HQDQAVLFF	0.7081	0.9844	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:09	KHQDQAVLF	0.7058	0.884	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C17:01	HQDQAVLFF	0.7013	0.8856	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:24	HQDQAVLFF	0.7003	0.9757	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B38:05	HQDQAVLFF	0.656	0.9847	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C07:04	KHQDQAVLF	0.6444	0.9494	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B40:21	HQDQAVLFF	0.6302	0.7451	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B18:04	HQDQAVLFF	0.6154	0.9211	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B39:11	KHQDQAVLF	0.6102	0.7266	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B40:12	HQDQAVLFF	0.5996	0.5995	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:13	HQDQAVLFF	0.5884	0.9392	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B40:49	HQDQAVLFF	0.5737	0.5757	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B39:11	HQDQAVLFF	0.5646	0.9258	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C04:04	KHQDQAVLF	0.5152	0.9126	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B18:07	HQDQAVLFF	0.5085	0.882	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-A02:14	HQDQAVLFF	0.5026	0.6455	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C02:10	HQDQAVLFF	0.4201	0.9787	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C02:02	HQDQAVLFF	0.4201	0.9787	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B18:08	HQDQAVLFF	0.4106	0.9191	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-C06:06	KHQDQAVLF	0.4043	0.9881	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:53	HQDQAVLFF	0.3949	0.9524	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:73	HQDQAVLFF	0.3714	0.984	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:54	HQDQAVLFF	0.3362	0.9411	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:09	HQDQAVLFF	0.3226	0.9418	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:30	HQDQAVLFF	0.226	0.9771	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:68	HQDQAVLFF	0.2096	0.8165	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B15:54	KHQDQAVLF	0.0777	0.8894	6	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B07:13	HQDQAVLFF	0.0148	0.8767	7	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B40:04	TEKHQDQAVL	0.9913	0.7056	4	14
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B40:36	TEKHQDQAVL	0.987	0.6235	4	14
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B38:05	EKHQDQAVLF	0.9867	0.8767	5	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B38:05	KHQDQAVLFF	0.9857	0.9544	6	16
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B40:49	TEKHQDQAVL	0.985	0.5887	4	14
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-A74:01	VLFFHLSRER	0.9729	0.5686	12	22
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B41:03	TEKHQDQAVL	0.7444	0.6522	4	14
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B44:07	TEKHQDQAVLF	0.9984	0.8292	4	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B44:13	TEKHQDQAVLF	0.9984	0.8292	4	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B44:26	TEKHQDQAVLF	0.9984	0.8292	4	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B18:11	TEKHQDQAVLF	0.9954	0.757	4	15
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	HLA-B38:05	TEKHQDQAVLF	0.9809	0.9272	4	15

Top

Potential FusionNeoAntigen Information of CEP170-AKT3 in HLA II

CEP170-AKT3_243349081_243736350.msa
CEP170-AKT3_243349561_243736350.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	DRB1-0807	DKLFFHLSRERVFSE	11	26
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	DRB1-0825	DKLFFHLSRERVFSE	11	26
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	DRB1-0834	DKLFFHLSRERVFSE	11	26
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	DRB1-0904	DKLFFHLSRERVFSE	11	26
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	DRB1-1172	DKLFFHLSRERVFSE	11	26
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	DRB1-1172	IDKLFFHLSRERVFS	10	25
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	DRB1-1216	DKLFFHLSRERVFSE	11	26
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	DRB1-1222	DKLFFHLSRERVFSE	11	26
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	DRB1-13100	DKLFFHLSRERVFSE	11	26
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	DRB1-13100	IDKLFFHLSRERVFS	10	25
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	DRB1-1326	DKLFFHLSRERVFSE	11	26
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	DRB1-1331	DKLFFHLSRERVFSE	11	26
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	DRB1-1346	DKLFFHLSRERVFSE	11	26
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	DRB1-1346	IDKLFFHLSRERVFS	10	25
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	DRB1-1386	DKLFFHLSRERVFSE	11	26
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	DRB1-1407	DKLFFHLSRERVFSE	11	26
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	DRB1-1413	DKLFFHLSRERVFSE	11	26
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	DRB1-1414	DKLFFHLSRERVFSE	11	26
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	DRB1-1436	DKLFFHLSRERVFSE	11	26
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	DRB1-1442	DKLFFHLSRERVFSE	11	26
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	DRB1-1444	DKLFFHLSRERVFSE	11	26
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	DRB1-1448	DKLFFHLSRERVFSE	11	26
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	DRB1-1449	DKLFFHLSRERVFSE	11	26
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	DRB1-1453	DKLFFHLSRERVFSE	11	26
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	DRB1-1468	DKLFFHLSRERVFSE	11	26
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	DRB1-1468	IDKLFFHLSRERVFS	10	25
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	DRB1-1469	DKLFFHLSRERVFSE	11	26
CEP170-AKT3	chr1	243349081	chr1	243736350	1618	DRB1-1493	DKLFFHLSRERVFSE	11	26
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	DRB1-1172	AVLFFHLSRERVFSE	11	26
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	DRB1-13100	AVLFFHLSRERVFSE	11	26
CEP170-AKT3	chr1	243349561	chr1	243736350	1324	DRB1-1346	AVLFFHLSRERVFSE	11	26

Top

Fusion breakpoint peptide structures of CEP170-AKT3

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
551	ARKMIDKLFFHLSR	CEP170	AKT3	chr1	243349081	chr1	243736350	1618

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
4277	KHQDQAVLFFHLSR	CEP170	AKT3	chr1	243349561	chr1	243736350	1324

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of CEP170-AKT3

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	551	ARKMIDKLFFHLSR	-7.9962	-8.1096
HLA-B14:02	3BVN	551	ARKMIDKLFFHLSR	-5.70842	-6.74372
HLA-B52:01	3W39	551	ARKMIDKLFFHLSR	-6.83737	-6.95077
HLA-B52:01	3W39	551	ARKMIDKLFFHLSR	-4.4836	-5.5189
HLA-A11:01	4UQ2	551	ARKMIDKLFFHLSR	-10.0067	-10.1201
HLA-A11:01	4UQ2	551	ARKMIDKLFFHLSR	-9.03915	-10.0745
HLA-A24:02	5HGA	551	ARKMIDKLFFHLSR	-6.56204	-6.67544
HLA-A24:02	5HGA	551	ARKMIDKLFFHLSR	-5.42271	-6.45801
HLA-B44:05	3DX8	551	ARKMIDKLFFHLSR	-7.85648	-8.89178
HLA-B44:05	3DX8	551	ARKMIDKLFFHLSR	-5.3978	-5.5112
HLA-A02:01	6TDR	551	ARKMIDKLFFHLSR	-3.37154	-4.40684
HLA-B14:02	3BVN	4277	KHQDQAVLFFHLSR	-7.37157	-7.48337
HLA-B14:02	3BVN	4277	KHQDQAVLFFHLSR	-5.75216	-6.79526
HLA-B52:01	3W39	4277	KHQDQAVLFFHLSR	-7.36854	-7.48034
HLA-B52:01	3W39	4277	KHQDQAVLFFHLSR	-4.42371	-5.46681
HLA-A11:01	4UQ2	4277	KHQDQAVLFFHLSR	-8.60667	-9.64977
HLA-A11:01	4UQ2	4277	KHQDQAVLFFHLSR	-5.54504	-5.65684
HLA-A24:02	5HGA	4277	KHQDQAVLFFHLSR	-7.65859	-7.77039
HLA-A24:02	5HGA	4277	KHQDQAVLFFHLSR	-6.03094	-7.07404
HLA-B44:05	3DX8	4277	KHQDQAVLFFHLSR	-5.82315	-5.93495
HLA-B44:05	3DX8	4277	KHQDQAVLFFHLSR	-2.98805	-4.03115

Top

Vaccine Design for the FusionNeoAntigens of CEP170-AKT3

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
CEP170-AKT3	chr1	243349081	chr1	243736350	12	22	KLFFHLSRER	AAGCTGTTTTTCCATTTGTCGAGAGAGCGG
CEP170-AKT3	chr1	243349081	chr1	243736350	6	15	ARKMIDKLF	GCAAGAAAAATGATTGACAAGCTGTTT
CEP170-AKT3	chr1	243349081	chr1	243736350	6	16	ARKMIDKLFF	GCAAGAAAAATGATTGACAAGCTGTTTTTC
CEP170-AKT3	chr1	243349081	chr1	243736350	7	16	RKMIDKLFF	AGAAAAATGATTGACAAGCTGTTTTTC
CEP170-AKT3	chr1	243349081	chr1	243736350	8	17	KMIDKLFFH	AAAATGATTGACAAGCTGTTTTTCCAT
CEP170-AKT3	chr1	243349081	chr1	243736350	8	18	KMIDKLFFHL	AAAATGATTGACAAGCTGTTTTTCCATTTG
CEP170-AKT3	chr1	243349081	chr1	243736350	9	18	MIDKLFFHL	ATGATTGACAAGCTGTTTTTCCATTTG
CEP170-AKT3	chr1	243349561	chr1	243736350	11	20	AVLFFHLSR	GCTGTTCTGTTTTTCCATTTGTCGAGA
CEP170-AKT3	chr1	243349561	chr1	243736350	11	22	AVLFFHLSRER	GCTGTTCTGTTTTTCCATTTGTCGAGAGAGCGG
CEP170-AKT3	chr1	243349561	chr1	243736350	12	22	VLFFHLSRER	GTTCTGTTTTTCCATTTGTCGAGAGAGCGG
CEP170-AKT3	chr1	243349561	chr1	243736350	4	14	TEKHQDQAVL	ACTGAAAAGCATCAAGACCAAGCTGTTCTG
CEP170-AKT3	chr1	243349561	chr1	243736350	4	15	TEKHQDQAVLF	ACTGAAAAGCATCAAGACCAAGCTGTTCTGTTT
CEP170-AKT3	chr1	243349561	chr1	243736350	5	14	EKHQDQAVL	GAAAAGCATCAAGACCAAGCTGTTCTG
CEP170-AKT3	chr1	243349561	chr1	243736350	5	15	EKHQDQAVLF	GAAAAGCATCAAGACCAAGCTGTTCTGTTT
CEP170-AKT3	chr1	243349561	chr1	243736350	6	14	KHQDQAVL	AAGCATCAAGACCAAGCTGTTCTG
CEP170-AKT3	chr1	243349561	chr1	243736350	6	15	KHQDQAVLF	AAGCATCAAGACCAAGCTGTTCTGTTT
CEP170-AKT3	chr1	243349561	chr1	243736350	6	16	KHQDQAVLFF	AAGCATCAAGACCAAGCTGTTCTGTTTTTC
CEP170-AKT3	chr1	243349561	chr1	243736350	7	15	HQDQAVLF	CATCAAGACCAAGCTGTTCTGTTT
CEP170-AKT3	chr1	243349561	chr1	243736350	7	16	HQDQAVLFF	CATCAAGACCAAGCTGTTCTGTTTTTC
CEP170-AKT3	chr1	243349561	chr1	243736350	9	18	DQAVLFFHL	GACCAAGCTGTTCTGTTTTTCCATTTG

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
CEP170-AKT3	chr1	243349081	chr1	243736350	10	25	IDKLFFHLSRERVFS	ATTGACAAGCTGTTTTTCCATTTGTCGAGAGAGCGGGTGTTCTCT
CEP170-AKT3	chr1	243349081	chr1	243736350	11	26	DKLFFHLSRERVFSE	GACAAGCTGTTTTTCCATTTGTCGAGAGAGCGGGTGTTCTCTGAG
CEP170-AKT3	chr1	243349561	chr1	243736350	11	26	AVLFFHLSRERVFSE	GCTGTTCTGTTTTTCCATTTGTCGAGAGAGCGGGTGTTCTCTGAG

Top

Information of the samples that have these potential fusion neoantigens of CEP170-AKT3

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
SKCM	CEP170-AKT3	chr1	243349081	ENST00000366542	chr1	243736350	ENST00000263826	TCGA-FS-A1ZD-06A
SKCM	CEP170-AKT3	chr1	243349561	ENST00000366542	chr1	243736350	ENST00000263826	TCGA-FS-A1ZD-06A

Top

Potential target of CAR-T therapy development for CEP170-AKT3

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to CEP170-AKT3

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to CEP170-AKT3

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)